Dyne Therapeutics to Participate in Upcoming Investor Conference
Dyne Therapeutics, Inc. announced that its management team is scheduled to participate in a fireside chat at the Jefferies Global Healthcare Conference in London.
Stocks · News reference
Why iSpecimen Shares Are Trading Higher By Around 28%; Here Are 20 Stocks Moving Premarket
iSpecimen surged 27.9% premarket on a $4.5M Foldlab AI asset deal; CEA Industries led gainers, while Focus Universal plunged 51.2%.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
bioAffinity Technologies Reports Record Monthly Testing Volume for CyPath Lung in October 2026
bioAffinity Technologies announced that its noninvasive lung cancer test, CyPath Lung, achieved record monthly testing volume during October 2026.
Onco-Innovations Limited Announces Termination of Performance-Based Funding Arrangement with Sorbie
Onco-Innovations Limited has entered into a termination agreement with Sorbie Bornholm LP and Sorbie Investments LLP to end their performance-based funding arrangement.
Novartis Reaches Key Milestone for Ianalumab Ahead of FDA Vote
Novartis has achieved a significant development milestone for its drug candidate ianalumab as it approaches a regulatory decision from the FDA.
Idiopathic Inflammatory Myositis Market Set for Strong Growth at 16.8% CAGR Through 2036, Driven by Rising Demand for Targeted Therapies | DelveInsight
The Idiopathic Inflammatory Myositis (IIM) market is projected to grow at 16.8% CAGR through 2036, reaching significant expansion driven by rising disease awareness, improved diagnostics, and an expanding pipeline of targeted therapies. The market was valued at USD 714 million across the 7MM in 2025, with the US accounting for 55% of the market. Multiple pharmaceutical companies are advancing investigational treatments addressing unmet medical needs in dermatomyositis, polymyositis, and inclusion body myositis.
Novartis Presents Two-Year Data for Ianalumab in Sjögren's Disease
Novartis presented two-year clinical data for ianalumab, demonstrating continued improvements in disease activity for patients with Sjögren's disease.